A synthesized peptide derived from human GCET2 Involved in the negative regulation of lymphocyte motility. It mediates the migration-inhibitory effects of IL6. Serves as a positive regulator of the RhoA signaling pathway. Enhancement of RhoA activation results in inhibition of lymphocyte and lymphoma cell motility by activation of its downstream effector ROCK. Is a regulator of B-cell receptor signaling, that acts through SYK kinase activation.
Konjugation:
Unconjugated
Anti-GCET2 Monoclonal Antibody . Tested in IHC, ICC/IF, Flow Cytometry applications. This antibody reacts with Human.